Skip to content

Search

CASSETTE: Clindamycin Adjunctive therapy for Severe Staphylococcus aurEus Treatment Evaluation, a multi-centre, pilot randomised controlled trial

Asha Tom Bowen Snelling BA MBBS DCH FRACP PhD GAICD FAHMS OAM BMBS DTMH GDipClinEpid PhD FRACP Head, Healthy Skin and ARF Prevention Head, Infectious

The Kids Research Institute Australia researchers take out prestigious Premier’s Science Awards

Three outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.

The Kids researchers named as finalists in 2023 Premier’s Science Awards

Five The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.

Healthy Skin and ARF Prevention

Our aim is for all kids to have healthy skin. We work with communities to reduce the burden of Strep A skin sores and sore throats to prevent rheumatic fever.

Resource hub

Working alongside the Healthy Skin & ARF Prevention team, clinicians and other researchers; Elder researchers and community members have driven the co-design of healthy skin promotion resources localised to their community.

Strong Skin App

Designed by community for community, the Strong Skin App is a go-to resource to support your skin health.

Standardization of Epidemiological Surveillance of Invasive Group A Streptococcal Infections

Invasive group A streptococcal (Strep A) infections occur when Streptococcus pyogenes, also known as beta-hemolytic group A Streptococcus, invades a normally sterile site in the body. This article provides guidelines for establishing surveillance for invasive Strep A infections. The primary objective of invasive Strep A surveillance is to monitor trends in rates of infection and determine the demographic and clinical characteristics of patients with laboratory-confirmed invasive Strep A infection, the age- and sex-specific incidence in the population of a defined geographic area, trends in risk factors, and the mortality rates and rates of nonfatal sequelae caused by invasive Strep A infections.

A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases

Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities.

Standardization of epidemiological surveillance of rheumatic heart disease

Rheumatic heart disease (RHD) is a long-term sequela of acute rheumatic fever (ARF), which classically begins after an untreated or undertreated infection caused by Streptococcus pyogenes (Strep A). RHD develops after the heart valves are permanently damaged due to ARF.

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.